Compass Financial Management LLC Makes New $312,000 Investment in Omeros Corporation $OMER

Compass Financial Management LLC bought a new stake in Omeros Corporation (NASDAQ:OMER) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 32,815 shares of the biopharmaceutical company’s stock, valued at approximately $312,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Omeros during the 4th quarter worth approximately $25,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Omeros in the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Omeros in the fourth quarter valued at about $33,000. Assetmark Inc. acquired a new stake in shares of Omeros during the first quarter worth about $38,000. Finally, Tower Research Capital LLC TRC lifted its position in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 11,971 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Trading Up 0.3%

Shares of Omeros stock opened at $19.32 on Tuesday. The company has a 50-day moving average of $11.93 and a two-hundred day moving average of $11.81. The stock has a market cap of $1.40 billion, a PE ratio of 15.09 and a beta of 2.54. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.58.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, sell-side analysts forecast that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on OMER shares. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Insider Activity

In related news, Director Thomas J. Cable sold 15,000 shares of Omeros stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director owned 35,067 shares in the company, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO David J. Borges sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the completion of the transaction, the chief accounting officer owned 5,000 shares in the company, valued at approximately $84,750. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.